Answers are grounded in this paper and cite their sources.
Background Trigeminal neuralgia (TN) is a severe neuropathic pain disorder characterised by paroxysmal, ‘electric shock’ like facial pain, substantial functional impairment and a reduced health-related quality of life. Concerningly, first-line pharmacological treatments, such as carbamazepine, are ineffective or poorly tolerated in up to one-third of patients. Objectives To assess the efficacy and tolerability of Sativex® (THC:CBD oromucosal spray) in patients with TN within the constraints of a heavily regulated National Health Service (NHS) in the UK; and to generate preliminary data to inform future larger-scaled studies. Methods This prospective, single-centre pilot study included three female patients with refractory TN, all of whom had previously undergone neurosurgical intervention and had trialled at least two pharmacological modalities unsuccessfully. Patients received Sativex and were followed at baseline, 4 weeks, 8 weeks, and 12 weeks. Quantitative outcomes included the Neuropathic Pain Scale (NPS) and Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scores for neuropathic pain and SF-36 total score to assess HrQoL. Analyses were primarily descriptive, with change-from-baseline calculations and exploratory Friedman tests performed for the three principal quantitative measures. Qualitative follow-up data were also reviewed to capture symptom change, functional impact, tolerability, and practical barriers to treatment use for each patient. Results Descriptive analyses found higher HrQoL scores at all follow-up timepoints than at baseline, with the greatest numerical increase observed by 8 weeks and broadly maintained at 12 weeks. Mean NPS and LANSS scores were lower than baseline across follow-up, illustrating reduced neuropathic pain levels although these changes were smaller and more heterogeneous. Exploratory Friedman tests were not statistically significant for any of the primary measures. Qualitative review demonstrated extensive heterogeneity in onset and magnitude of response, with functional improvements reported in some patients alongside important tolerability and practical barriers. Conclusion These preliminary findings suggest that Sativex may be associated with improvement in HrQoL and a reduction in pain-related symptom burden in some patients with refractory TN, although response was heterogeneous and limited by tolerability and practical treatment barriers. Larger prospective studies are needed to better define clinical effectiveness, durability of response, and meaningful patient-centred outcome measures.
No takes yet. Share an insight, caveat, or question.
Bryan et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: